Status:
COMPLETED
Specific Effects of Escitalopram on Neuroendocrine Response
Lead Sponsor:
Queen's University
Collaborating Sponsors:
H. Lundbeck A/S
Conditions:
Healthy
Eligibility:
All Genders
18-59 years
Brief Summary
Citalopram, a selective serotonin reuptake inhibitor (SSRI), is used as a neuroendocrine probe in human subjects to assess serotonin (5-hydroxytryptamine; 5-HT) function as reflected in prolactin and ...
Detailed Description
See above.
Eligibility Criteria
Inclusion
- The age range will be restricted to between 18 and 59 years of age.
- Subjects must be fit and have no history of significant illness.
- Subjects must have no risk factors for HIV or viral hepatitis.
- Subjects must be non-smokers, free of medication, and consume alcoholic and caffeinated beverages in moderation.
- Subjects must also be in good psychological health with no history of psychiatric illness.
Exclusion
- Personal history of psychiatric illness, habitual smoking, illicit or prescription drug use, high intake of alcohol (\>10 drinks/week) or caffeine (\>500 mg caffeine/day), shift work, pregnancy, personal or familial history of seizures, significant medical illness or treatment in the last six months, significant physical or laboratory abnormalities, or current use of a weight loss diet.
- Women entering the study must be on a reliable form of birth control, i.e., tubal ligation, hysterectomy, oral contraceptives, abstinence, or vasectomy in partner.
Key Trial Info
Start Date :
September 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2007
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT00150527
Start Date
September 1 2005
End Date
December 1 2007
Last Update
February 5 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Providence Centre, Mental Health Services
Kingston, Ontario, Canada, K7L 4X3